

IMI impact on paediatric medicine | 10 November 2021

Speaker bio



Solange Corriol-Rohou

Sr Global Policy Director, AstraZeneca R&D

Solange Corriol-Rohou, a pulmonologist and an immuno-allergist by training, joined AZ R&D in 2004 and is currently Sr. Global Policy Director, with some responsibility in the respiratory/infection franchise.

Over the past 20 years, moving from the French Medicines Agency/EMA and a specialist physician position at the Hospital of Versailles (France) to the pharmaceutical industry, she has gained strategic experience in drug development, in respiratory, inflammation and oncology.

She is also currently leading the AZ Paediatric Work Group. Solange, in her role as the chair of the Clinical Development Expert Group at the EFPIA, organized jointly with the EMA several workshops (e.g. Modelling & Simulation, Dose Finding/Dose Response, Paediatric Extrapolation).

She has recently been involved in critical issues, such as Complex Clinical Trial Designs, the use of Digital tools in drug development or paediatric unmet medical needs. She has also experience working in IMI projects (PROactive in COPD, ADAPT SMART, U-BIOPRED, Get Real, Trials@Home and Mobilise-D). Within ICH, as the EFPIA topic leader, she has participated in the revision of the ICH E11 paediatric guideline and is currently keeping the momentum with the ICH E11A Paediatric Extrapolation Guideline to be released in early 2022